Gold prices steady with focus on Ukraine-Russia, Jackson Hole
ORLANDO - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a pharmaceutical company whose stock has surged nearly 89% over the past six months, has announced the schedule for its upcoming preferred stock dividend. The company, currently valued at $86.37 million, will distribute one preferred share for every four common shares held to shareholders of record on July 25, 2025, with distribution set for August 5. According to InvestingPro data, this marks the company’s first dividend initiative, as it historically hasn’t paid dividends to shareholders.
Each preferred share will be convertible to one common share following FDA approval of the company’s AVERSA Fentanyl product. Unconverted preferred shares will be entitled to an annual cash dividend from company profits, as determined by the board of directors. The company maintains a healthy financial position with a current ratio of 3.71, indicating strong ability to meet short-term obligations.
Nutriband’s primary focus is developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating the company’s AVERSA technology. This technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The company’s AVERSA technology is protected by patents granted in multiple countries including the United States, Europe, Japan, China, and Australia, according to the press release statement.
Nutriband describes itself as primarily engaged in developing transdermal pharmaceutical products, with its AVERSA technology capable of being incorporated into any transdermal patch to prevent the abuse of drugs with abuse potential.
The announcement comes as the company continues development of its pharmaceutical portfolio focused on transdermal drug delivery systems. While posting 18.92% revenue growth in the last twelve months, analysts maintain a strong buy rating with a $15 price target. InvestingPro analysis suggests the stock may be undervalued, with additional insights available to subscribers.
In other recent news, NutriBand Inc. has made several notable announcements. The company has authorized a new class of Series A Convertible Preferred Stock, with up to 2,788,678 shares available for issuance. A 25% preferred stock dividend has also been declared, allowing shareholders to receive one preferred share for every four common shares owned, effective as of the July 25, 2025 record date. NutriBand’s preferred shares will convert to common shares following FDA approval of its AVERSA Fentanyl product, and holders can receive dividends if not converted.
Additionally, NutriBand secured a U.S. patent for its AVERSA™ abuse deterrent technology, expanding its intellectual property rights in the United States and complementing existing patents in 46 countries. The company projects strong sales for its AVERSA Fentanyl patches, estimating peak annual sales between $80 million and $200 million, with plans to launch AVERSA Buprenorphine next. NutriBand has also achieved significant advancements in its manufacturing processes and established a commercial supply chain to meet FDA standards. The company continues to explore international partnerships and licensing opportunities for its AVERSA intellectual property.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.